Mechanism of Action
GC-C Receptor Signaling
GC-C is a receptor guanylyl cyclase expressed on intestinal epithelial cells and hypothalamic neurons. Uroguanylin binding activates the intrinsic cyclase domain, raising intracellular cGMP. In intestinal epithelium: cGMP activates CFTR chloride channels and inhibits NHE3 (Na+/H+ exchanger), increasing luminal fluid and bicarbonate secretion. Intestinal motility is also stimulated through downstream enteric neuron activation.
Hypothalamic Satiety Signaling
GC-C receptors in the hypothalamic ventromedial nucleus (VMH) mediate uroguanylin's central satiety effects. IV or ICV uroguanylin reduces food intake in rodents; GC-C knockout mice are obese and hyperphagia. After bariatric surgery (Roux-en-Y bypass), uroguanylin levels rise markedly, potentially contributing to long-term appetite suppression. This central GC-C/cGMP satiety axis is distinct from GLP-1 and PYY pathways, offering a novel target for obesity pharmacotherapy.
Research Summary
Obesity and Satiety
Active ResearchGC-C knockout mice develop obesity from hyperphagia. Uroguanylin or GC-C agonist infusion reduces food intake in diet-induced obese mice by 30-40%. Post-bariatric surgery, uroguanylin levels increase substantially, correlating with improved appetite control. Phase 1/2 trials of intranasal uroguanylin and GC-C agonists for obesity are underway, targeting the hypothalamic arm without full intestinal secretory stimulation.
GI Function (Analogs: Plecanatide, Linaclotide)
Clinical Validation (Analogs)Plecanatide (a uroguanylin analog) and linaclotide (a guanylin analog) are FDA-approved for chronic idiopathic constipation and IBS-C. Both activate intestinal GC-C, raising cGMP and increasing luminal fluid. cGMP also reduces visceral hypersensitivity by inhibiting pain signal transmission from submucosal afferents, explaining their efficacy for IBS abdominal pain beyond laxative effect.
Calculate your Uroguanylin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Satiety/obesity research | 100-300 pmol/kg IV or 1-10 nmol ICV in rodents | Per session | IV or ICV |
| GI motility research | 1-10 nM luminal in intestinal preparations | Per experiment | Luminal/in vitro |
Native uroguanylin rapidly degraded in plasma; stable analogs needed for systemic delivery. Intranasal delivery being explored for CNS satiety effects without full GI stimulation.
Interactions
Safety Profile
Uroguanylin research doses in animals: diarrhea at high doses, reflecting the GC-C secretory mechanism. Plecanatide and linaclotide (GC-C analogs) cause diarrhea as primary adverse effect in 5-16% of clinical trial patients; usually manageable with dose reduction. Black box warning for linaclotide/plecanatide in pediatric patients under 6 years (severe diarrhea risk). No systemic toxicity expected given minimal GI absorption of uroguanylin. Intranasal delivery for hypothalamic satiety would avoid intestinal GC-C stimulation and associated diarrhea.
References
- [1]Hamra FK, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA. 1993;90(22):10464-10468.
- [2]Valentino MA, et al. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011;121(9):3578-3588.